Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.63 |
| ▸ | TYMS | P04818 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064249 | 1.00 | DUT (0.63) | DUTTYMS | |
| SCHEMBL15810769 | 0.90 | P2RY2 (0.66) | DUT | |
| Deoxyuridine Monophosphate SCHEMBL25024676 | 0.89 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL8200 | 0.89 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL888328 | 0.89 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL21941035 | 0.89 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL9830961 | 0.85 | DUT (0.72) | DUTTYMS | |
| SCHEMBL28552817 | 0.83 | TK1 (0.59) | — | |
| SCHEMBL8338549 | 0.83 | TK1 (0.59) | — | |
| SCHEMBL440592 | 0.83 | TK1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007083173-A2 | MONONUCLEOTIDES AND MONONUCLEOSIDES FOR USE IN THERAPY | UNIVERSITY OF DEBRECEN (HU) | 2007-07-26 | — | — | WO | disclosed |
| US-20030216334-A1 | Methods for inhibiting/treating hiv infections and aids related symptoms | THEREX TECHNOLOGIES, INC. | 2003-11-20 | — | — | US | disclosed |
| US-20030216334-A1 | Methods for inhibiting/treating hiv infections and aids related symptoms | THEREX TECHNOLOGIES, INC. | 2003-11-20 | — | — | US | disclosed |
| EP-1248631-A1 | METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS | Therex Technologies, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1248631-A1 | METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS | Therex Technologies, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001049297-A8 | METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS | THEREX TECHNOLOGIES INC (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001049297-A1 | METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS | THEREX TECHNOLOGIES, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001049297-A1 | METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS | THEREX TECHNOLOGIES, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216334-A1 | Methods for inhibiting/treating hiv infections and aids related symptoms | DUT, SAMHD1, TYMP | DUT 1/4885TYMS 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.